Bruce J. Dezube

17.7k total citations · 1 hit paper
196 papers, 9.0k citations indexed

About

Bruce J. Dezube is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Bruce J. Dezube has authored 196 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Oncology, 56 papers in Pathology and Forensic Medicine and 49 papers in Molecular Biology. Recurrent topics in Bruce J. Dezube's work include Viral-associated cancers and disorders (80 papers), Lymphoma Diagnosis and Treatment (53 papers) and HIV/AIDS drug development and treatment (23 papers). Bruce J. Dezube is often cited by papers focused on Viral-associated cancers and disorders (80 papers), Lymphoma Diagnosis and Treatment (53 papers) and HIV/AIDS drug development and treatment (23 papers). Bruce J. Dezube collaborates with scholars based in United States, United Kingdom and Israel. Bruce J. Dezube's co-authors include Liron Pantanowitz, David M. Aboulafia, Geoffrey I. Shapiro, Lawrence D. Kaplan, Donald W. Northfelt, Susan E. Krown, Jorge J. Castillo, Antoinette R. Tan, Jeannette Y. Lee and Donald P. Lawrence and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Bruce J. Dezube

189 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

2019 314 citations Antoinette R. Tan, Bruce J. Dezube et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruce J. Dezube United States	48	5.4k	2.5k	2.0k	1.5k	1.1k	196	9.0k
Martine Raphaël France	53	6.7k 1.2×	1.1k 0.4×	5.1k 2.5×	2.1k 1.4×	1.5k 1.4×	207	10.8k
Luigi Maria Larocca Italy	54	3.3k 0.6×	3.5k 1.4×	2.0k 1.0×	906 0.6×	301 0.3×	338	10.4k
Franco Dammacco Italy	72	4.3k 0.8×	5.9k 2.4×	1.7k 0.9×	2.1k 1.4×	452 0.4×	385	17.0k
Marinus H. J. van Oers Netherlands	53	2.8k 0.5×	1.9k 0.7×	2.8k 1.4×	715 0.5×	454 0.4×	175	9.0k
Christer Sundström Sweden	54	3.8k 0.7×	3.0k 1.2×	5.0k 2.5×	864 0.6×	362 0.3×	270	12.3k
Crystal L. Mackall United States	61	7.1k 1.3×	3.2k 1.3×	666 0.3×	1.3k 0.9×	791 0.7×	168	16.1k
Amy Chadburn United States	67	8.4k 1.6×	6.0k 2.4×	6.7k 3.4×	1.6k 1.1×	1.4k 1.2×	246	19.0k
Kishor Bhatia United States	43	3.8k 0.7×	2.1k 0.9×	1.9k 0.9×	653 0.4×	483 0.4×	156	6.1k
Jan W. Gratama Netherlands	48	3.7k 0.7×	1.6k 0.6×	904 0.5×	1.2k 0.8×	541 0.5×	216	7.6k
James M. Pluda United States	43	2.0k 0.4×	2.3k 0.9×	887 0.4×	803 0.5×	1.4k 1.2×	87	6.0k

Countries citing papers authored by Bruce J. Dezube

Since Specialization

Citations

This map shows the geographic impact of Bruce J. Dezube's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce J. Dezube with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce J. Dezube more than expected).

Fields of papers citing papers by Bruce J. Dezube

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce J. Dezube. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce J. Dezube. The network helps show where Bruce J. Dezube may publish in the future.

Co-authorship network of co-authors of Bruce J. Dezube

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce J. Dezube. A scholar is included among the top collaborators of Bruce J. Dezube based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce J. Dezube. Bruce J. Dezube is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Swords, Ronan, Steven Coutré, Michael B. Maris, et al.. (2016). Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML). Blood. 128(22). 98–98. 7 indexed citations

Shah, Jatin J., Andrzej Jakubowiak, Owen A. O’Connor, et al.. (2015). Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 22(1). 34–43. 162 indexed citations

Sarantopoulos, John, Geoffrey I. Shapiro, Roger B. Cohen, et al.. (2015). Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 847–857. 139 indexed citations

Lacouture, Mario E., John C. Morris, Donald P. Lawrence, et al.. (2015). Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunology Immunotherapy. 64(4). 437–446. 117 indexed citations

Shapiro, Geoffrey I., Eunice L. Kwak, Bruce J. Dezube, et al.. (2014). First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 21(1). 87–97. 75 indexed citations

Hong, David S., Razelle Kurzrock, Jeffrey G. Supko, et al.. (2012). A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 18(12). 3396–3406. 197 indexed citations

Deeken, John F., Liron Pantanowitz, & Bruce J. Dezube. (2009). Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Current Opinion in Oncology. 21(5). 445–454. 39 indexed citations

Sullivan, Ryan J., Liron Pantanowitz, & Bruce J. Dezube. (2009). Targeted Therapy for Kaposi Sarcoma. BioDrugs. 23(2). 69–75. 32 indexed citations

Shapiro, Geoffrey I., E. Heath, Lisa Malburg, et al.. (2007). A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies. Molecular Cancer Therapeutics. 6. 8 indexed citations

10.

Hong, David S., Razelle Kurzrock, Jeffrey G. Supko, et al.. (2007). Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies. Molecular Cancer Therapeutics. 6. 4 indexed citations

11.

Caponetti, Gabriel C., Bruce J. Dezube, Carlos S. Restrepo, & Liron Pantanowitz. (2007). Kaposi sarcoma of the musculoskeletal system. Cancer. 109(6). 1040–1052. 49 indexed citations

12.

Pantanowitz, Liron & Bruce J. Dezube. (2006). Kaposi sarcoma of the larynx.. PubMed. 16(4). 194–5. 2 indexed citations

13.

Pantanowitz, Liron, Bruce J. Dezube, Sonia Hernandez‐Barrantes, Steven R. Tahan, & Mustafa Kh. Dabbous. (2006). Matrix metalloproteinases in the progression and regression of Kaposi’s sarcoma. Journal of Cutaneous Pathology. 33(12). 793–798. 22 indexed citations

14.

Raggo, Camilo, Rebecca Ruhl, Shane C. McAllister, et al.. (2005). Novel Cellular Genes Essential for Transformation of Endothelial Cells by Kaposi's Sarcoma–Associated Herpesvirus. Cancer Research. 65(12). 5084–5095. 99 indexed citations

15.

Fätkenheuer, Gerd, Anton Pozniak, Margaret Johnson, et al.. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Medicine. 11(11). 1170–1172. 386 indexed citations

16.

Aboulafia, David M., Liron Pantanowitz, & Bruce J. Dezube. (2004). AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART.. PubMed. 14(11). 605–17. 32 indexed citations

17.

Koon, Henry, Glenn J. Bubley, Liron Pantanowitz, et al.. (2004). Imatinib-Induced Regression of AIDS-Related Kaposi's Sarcoma. Journal of Clinical Oncology. 23(5). 982–989. 115 indexed citations

18.

Northfelt, Donald W., Bruce J. Dezube, James Thommes, et al.. (1998). Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.. Journal of Clinical Oncology. 16(7). 2445–2451. 485 indexed citations

19.

Choe, Hyeryun, Bruce J. Dezube, Michael Farzan, et al.. (1998). The Bis-Azo Compound FP-21399 Inhibits HIV-1 Replication by Preventing Viral Entry. Virology. 244(2). 530–541. 20 indexed citations

20.

Dezube, Bruce J., et al.. (1993). Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: A pilot study. Cancer Immunology Immunotherapy. 36(1). 57–60. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact